ProPhase Labs to be Delisted from Nasdaq; Trading Suspension Effective January 5, 2026
Summary
ProPhase Labs received a delisting notice from Nasdaq for failing to meet the minimum bid price requirement, with trading suspension effective January 5, 2026. The company plans to appeal and seek quotation on OTC Markets.
Key Events
-
Nasdaq Delisting Notice Received
On December 29, 2025, ProPhase Labs, Inc. received a letter from Nasdaq indicating non-compliance with the minimum bid price rule (5550(a)(2)).
-
Trading Suspension Imminent
Trading of the company's common stock on Nasdaq will be suspended at the opening of business on January 5, 2026, followed by Nasdaq filing a Form 25 to delist the securities.
-
Company Plans Appeal and OTC Listing
ProPhase Labs intends to request a hearing before the Nasdaq Hearings Panel to appeal the staff determination and is currently applying for quotation of its common stock on the OTC Markets.
Analysis
ProPhase Labs received a formal notice from Nasdaq indicating its common stock will be delisted due to failure to maintain the minimum $1.00 bid price. This is a significant negative event as delisting from a major exchange like Nasdaq can severely impact a company's liquidity, investor visibility, and institutional ownership. While the company intends to appeal the decision and apply for quotation on the OTC Markets, the imminent trading suspension on Nasdaq signals a challenging period ahead for shareholders, often leading to reduced trading volume and a less regulated trading environment.
At the time of this filing, PRPH was trading at $0.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $0.30 to $9.35. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.